Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

The trial’s results, expected by June 2025, could significantly impact the company’s position in the diabetes treatment ... favoring Wegovy over Zepbound, may affect Eli Lilly’s market dynamics.

The 30-stock Dow lost 44.14 points, or 0.10%, and ended at 42,171.66. The S&P 500 slipped 0.03% to close at 5,980.87, and the ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

It's up there from a financial perspective, but also just from a cultural impact perspective ... the most valuable companies in Europe by stock market capitalization, thanks to the spectacular ...